Office of Testing and Research, Office of Pharmaceutical Quality, Food and Drug Administration, St. Louis, MO, United States.
Office of Research and Standards, Office of Generic Drugs, Food and Drug Administration, Silver Spring, MD, United States.
J Pharm Sci. 2021 Jul;110(7):2778-2788. doi: 10.1016/j.xphs.2021.03.005. Epub 2021 Mar 10.
Particle size characterization for active pharmaceutical ingredients (APIs) in nasal spray suspension products presents unique challenges because both the API and excipient particles are present in the final dosage form. Currently, an established method is lacking because traditional particle sizing technologies do not distinguish the chemical identity of the particles. In this study, a non-destructive, ingredient-specific particle sizing method was developed for characterization of mometasone furoate (MF) nasal spray suspensions using Morphology Directed Raman Spectroscopy (MDRS). A five-step method development procedure was used in this study: sample preparation, particle imaging and morphology analysis, particle Raman measurements and classification, morphology filter selection, and minimum number of particles determination. Wet dispersion sample preparation method was selected to ensure that the particles were measured in their original suspended state. A training set containing over 10,000 randomly-selected particles, including both the API and excipient particles, was used to gain a comprehensive understanding of particle size, shape, and chemical ID for the nasal spray suspension. Morphology and Raman measurements were performed on each particle in the training set. The measurement results suggested that the aspect ratio and intensity mean filter combination was an appropriate morphology filter setting to selectively target API particles and exclude most of excipient particles. With further optimization of the morphology filter cutoff values and determination of minimal number of particles to be measured, the total measurement time was reduced from 90 hours to 8 hours. The morphologically screening strategy ultimately allowed us to create a time-efficient practical API-specific particle size distribution (PSD) methods for nasal spray suspensions. This study shows that MDRS is a fit for purpose analytical technique for determining ingredient-specific PSDs of the pharmaceutical formulation studied in this work.
用于鼻喷雾剂混悬剂产品的原料药 (API) 的粒度表征带来了独特的挑战,因为 API 和赋形剂颗粒都存在于最终的剂型中。目前,由于传统的颗粒粒度技术无法区分颗粒的化学特性,因此缺乏一种既定的方法。在这项研究中,使用形态导向拉曼光谱 (MDRS) 为糠酸莫米松 (MF) 鼻喷雾剂混悬剂开发了一种非破坏性的、特定于成分的颗粒粒度测定方法。本研究采用了五步方法开发程序:样品制备、颗粒成像和形态分析、颗粒拉曼测量和分类、形态学过滤器选择和最小颗粒数确定。选择湿分散样品制备方法以确保颗粒以其原始悬浮状态进行测量。包含超过 10,000 个随机选择的颗粒的训练集,包括 API 和赋形剂颗粒,用于全面了解鼻喷雾剂混悬剂的粒径、形状和化学 ID。在训练集中对每个颗粒进行形态和拉曼测量。测量结果表明,纵横比和强度均值过滤器组合是一种合适的形态过滤器设置,可以有选择地针对 API 颗粒并排除大多数赋形剂颗粒。通过进一步优化形态过滤器截止值并确定要测量的最小颗粒数,总测量时间从 90 小时减少到 8 小时。形态筛选策略最终使我们能够为鼻喷雾剂混悬剂创建一种高效、实用的 API 特定粒度分布 (PSD) 方法。本研究表明,MDRS 是一种适合用于确定本研究中所研究药物制剂的成分特定 PSD 的分析技术。